High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Diagnostic Molecular Pathology Pub Date : 2013-06-01 DOI:10.1097/PDM.0b013e318277448e

Imane Tabyaoui, Nadia Tahiri-Jouti, Zineb Serhier, Khadija El Maani, Siham Cherkaoui, Mounia Al Zemmouri, Mohamed B Othmani, Soumaya Zamiati

{"title":"High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.","authors":"Imane Tabyaoui, Nadia Tahiri-Jouti, Zineb Serhier, Khadija El Maani, Siham Cherkaoui, Mounia Al Zemmouri, Mohamed B Othmani, Soumaya Zamiati","doi":"10.1097/PDM.0b013e318277448e","DOIUrl":null,"url":null,"abstract":"<p><p>MYCN protooncogene status was assessed for the first time in Morocco in peripheral neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Correlations with age at diagnosis, stage, mitosis-karyorrhexis index, differentiation, and Shimada histology were evaluated. Thirty-six formalin-fixed, paraffin-embedded peripheral neuroblastic tumor tissue specimens collected between 2007 and 2010 from the Pathology Department were assessed for MYCN amplification using fluorescence in situ hybridization. MYCN amplification was found in 27.8% of cases. An association of MYCN amplification with unfavorable Shimada grading, higher mitosis-karyorrhexis index, and undifferentiated morphologic phenotype was found. We found no correlation with older age, advanced stage, or the presence of metastasis. Our results suggested that the presence of MYCN amplification is a strong biological indicator of a poor outcome and aggressive disease in neuroblastoma and nodular ganglioneuroblastoma.</p>","PeriodicalId":11235,"journal":{"name":"Diagnostic Molecular Pathology","volume":"22 2","pages":"112-8"},"PeriodicalIF":0.0000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/PDM.0b013e318277448e","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic Molecular Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PDM.0b013e318277448e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

MYCN protooncogene status was assessed for the first time in Morocco in peripheral neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Correlations with age at diagnosis, stage, mitosis-karyorrhexis index, differentiation, and Shimada histology were evaluated. Thirty-six formalin-fixed, paraffin-embedded peripheral neuroblastic tumor tissue specimens collected between 2007 and 2010 from the Pathology Department were assessed for MYCN amplification using fluorescence in situ hybridization. MYCN amplification was found in 27.8% of cases. An association of MYCN amplification with unfavorable Shimada grading, higher mitosis-karyorrhexis index, and undifferentiated morphologic phenotype was found. We found no correlation with older age, advanced stage, or the presence of metastasis. Our results suggested that the presence of MYCN amplification is a strong biological indicator of a poor outcome and aggressive disease in neuroblastoma and nodular ganglioneuroblastoma.

查看原文本刊更多论文

摩洛哥一系列神经母细胞肿瘤中MYCN扩增的高发生率:与当前生物学数据的比较

在摩洛哥首次评估了MYCN原癌基因在周围神经母细胞肿瘤中的状态，包括神经母细胞瘤、神经节神经母细胞瘤和神经节神经瘤。评估与诊断年龄、分期、有丝分裂-核裂指数、分化和岛田组织学的相关性。采用荧光原位杂交技术对2007年至2010年病毒科收集的36例福尔马林固定石蜡包埋的周围神经母细胞肿瘤组织标本进行MYCN扩增评估。27.8%的病例存在MYCN扩增。发现MYCN扩增与不利的岛田分级、较高的有丝分裂-核分裂指数和未分化的形态表型相关。我们没有发现与年龄、晚期或转移的存在相关。我们的研究结果表明，MYCN扩增的存在是神经母细胞瘤和结节神经节神经母细胞瘤预后不良和侵袭性疾病的一个强有力的生物学指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diagnostic Molecular Pathology 医学-病理学

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Diagnostic Molecular Pathology focuses on providing clinical and academic pathologists with coverage of the latest molecular technologies, timely reviews of established techniques, and papers on the applications of these methods to all aspects of surgical pathology and laboratory medicine. It publishes original, peer-reviewed contributions on molecular probes for diagnosis, such as tumor suppressor genes, oncogenes, the polymerase chain reaction (PCR), and in situ hybridization. Articles demonstrate how these highly sensitive techniques can be applied for more accurate diagnosis.